Proton Beam Radiation Therapy for Adults With Surgically Removed N2 Non-Small Cell Lung Cancer

What this Trial Is About

This clinical trial evaluates proton beam radiation therapy in patients with non-small cell lung cancer who have had surgery to remove their tumor and have cancer involvement in the middle chest lymph nodes N2. The study aims to assess the safety of proton beam radiation therapy and its potential benefits compared to conventional radiation after surgery, as well as to explore radiations impact on the immune system and overall patient outcomes. Participants undergo radiation treatment planning followed by proton beam radiation therapy. Blood samples are collected during the study to analyze the radiation dose to the immune system. The study includes a single treatment phase with follow-up lasting 24 months after the first radiation dose to monitor safety, disease recurrence, and survival. Throughout the study, participants will be monitored for any adverse events up to 90 days after enrollment. Researchers will assess radiation doses to immune cells before treatment and track disease-free and overall survival for up to two years. Participants are expected to comply with scheduled visits, tests, and treatment plans during the study period, allowing researchers to gather safety and efficacy data.

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer